Want to join the conversation?
$VRTX's revenues increased significantly in 2015 as compared to 2014, primarily due to cystic fibrosis treating drug Orkambi net product revenues, which commenced in 3Q15, and a $167.9MM increase in Kalydeco net product revenues, partially offset by a $43.6MM decrease in its collaborative revenues.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.